PIPR Stock Analysis: Piper Sandler Companies | NYSE
Capital Markets | NYSE, USA | Market Cap: 5.145m USD | 12M Return: 1% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 43.9M
EPS Trend: 99.4%
Qual. Beats: 0
Rev. Trend: 96.0%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Piper Sandler Companies is a U.S.-headquartered investment bank and institutional securities firm that provides investment banking, institutional sales and trading, research, and advisory services to corporations, private equity groups, public entities, non-profits, and institutional investors in the United States and abroad. The company was founded in 1895 in Minneapolis, Minnesota, was previously known as Piper Jaffray Companies, and adopted its current name in January 2020.
The firm operates across several core business areas, including corporate advisory (mergers and acquisitions, equity and debt financings, private placements, restructuring, and debt capital markets advisory), public finance investment banking serving state and local governments, special districts, and sectors such as education, healthcare, housing, and transportation, as well as municipal financial advisory and loan placement, and over-the-counter derivative products. It also provides equity and fixed income trade execution, fundamental equity and macro research, and fixed income sales and trading solutions to clients including banks, registered investment advisors, credit unions, asset managers, and insurance companies.
In addition, Piper Sandler runs an alternative asset management platform that invests firm capital and manages outside capital through merchant banking and healthcare-focused funds. The company is listed on the NYSE under the ticker PIPR, is classified within the GICS Financials sector under the Investment Banking & Brokerage sub-industry, and as a mid-cap firm it is generally oriented toward middle-market advisory and capital markets transactions rather than the bulge-bracket global investment banks.
- M&A advisory revenue rises on private equity deal pipeline
- Municipal bond issuance volumes recover as Fed cuts rates
- Biotech IPO rebound lifts equity capital markets advisory fees
| Net Income: 281.7m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.27 > 0.02 and ΔFCF/TA 11.54 > 1.0 |
| NWC/Revenue: 35.46% < 20% (prev 17.21%; Δ 18.25% < -1%) |
| CFO/TA 0.28 > 3% & CFO 596.6m > Net Income 281.7m |
| Net Debt (-135.0m) to EBITDA (462.6m): -0.29 < 3 |
| Current Ratio: 13.40 > 1.5 & < 3 |
| Outstanding Shares: last quarter (71.2m) vs 12m ago -0.85% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 101.2% > 50% (prev 82.50%; Δ 18.67% > 0%) |
| Interest Coverage Ratio: 101.2 > 6 (EBIT TTM 434.7m / Interest Expense TTM 4.29m) |
| A: 0.33 (Total Current Assets 765.7m - Total Current Liabilities 57.1m) / Total Assets 2.13b |
| B: 0.32 (Retained Earnings 680.5m / Total Assets 2.13b) |
| C: 0.22 (EBIT TTM 434.7m / Avg Total Assets 1.98b) |
| D: 2.35 (Book Value of Equity 1.34b / Total Liabilities 572.2m) |
| Altman-Z'' = 7.16 = AAA |
| DSRI: 0.86 (Receivables 197.5m/173.6m, Revenue 2.00b/1.50b) |
| GMI: 1.02 (GM 99.63% / 97.34%) |
| AQI: 0.77 (AQ_t 0.58 / AQ_t-1 0.75) |
| SGI: 1.33 (Revenue 2.00b / 1.50b) |
| TATA: -0.15 (NI 281.7m - CFO 596.6m) / TA 2.13b) |
| Beneish M = -3.04 (Cap -4..+1) = AA |
As of July 06, 2026, the stock is trading at USD 71.09 with a total of 896,700 shares traded. Over the past week, the price has changed by -8.46%, over one month by -7.28%, over three months by -8.68% and over the past year by +1.02%.
Current recommended Stop Loss: 67.40 (which is 5.2% or 1.4 ATR below the current price).
Piper Sandler Companies has received a consensus analysts rating of 3.00. Therefore, it is recommended to hold PIPR.
- StrongBuy: 0
- Buy: 0
- Hold: 4
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 95.1 | 33.8% |
P/E Trailing = 19.1788
P/E Forward = 10.1112
P/S = 2.5516
P/B = 3.8346
P/EG = 1.2623
Revenue TTM = 2.00b USD
EBIT TTM = 434.7m USD
EBITDA TTM = 462.6m USD
Long Term Debt = 97.2m USD (estimated: total debt 112.2m - short term 15.0m)
Short Term Debt = 15.0m USD (from shortTermDebt, last quarter)
Debt = 209.4m USD (from shortLongTermDebtTotal, last quarter) + Leases 97.2m
Net Debt = -135.0m USD (calculated: Debt 209.4m - CCE 344.4m)
Enterprise Value = 5.01b USD (5.15b + Debt 209.4m - CCE 344.4m)
Interest Coverage Ratio = 101.2 (Ebit TTM 434.7m / Interest Expense TTM 4.29m)
EV/FCF = 8.78x (Enterprise Value 5.01b / FCF TTM 571.0m)
FCF Yield = 11.40% (FCF TTM 571.0m / Enterprise Value 5.01b)
FCF Margin = 28.57% (FCF TTM 571.0m / Revenue TTM 2.00b)
Net Margin = 14.09% (Net Income TTM 281.7m / Revenue TTM 2.00b)
Gross Margin = unknown ((Revenue TTM 2.00b - Cost of Revenue TTM 53.2m) / Revenue TTM)
Tobins Q-Ratio = 2.35 (Enterprise Value 5.01b / Total Assets 2.13b)
Interest Expense / Debt = 2.05% (Interest Expense 4.29m / Debt 209.4m)
Taxrate = 24.83% (107.5m / 433.0m)
NOPAT = 326.8m (EBIT 434.7m * (1 - 24.83%))
Current Ratio = 13.40 (Total Current Assets 765.7m / Total Current Liabilities 57.1m)
Debt / Equity = 0.16 (Debt 209.4m / totalStockholderEquity, last quarter 1.34b)
Debt / EBITDA = -0.29 (Net Debt -135.0m / EBITDA 462.6m)
Debt / FCF = -0.24 (Net Debt -135.0m / FCF TTM 571.0m)
Total Stockholder Equity = 1.31b (last 4 quarters mean from totalStockholderEquity)
RoA = 14.26% (Net Income 281.7m / Total Assets 2.13b)
RoE = 21.56% (Net Income TTM 281.7m / Total Stockholder Equity 1.31b)
RoCE = 30.97% (EBIT 434.7m / Capital Employed (Equity 1.31b + L.T.Debt 97.2m))
RoIC = 16.44% (NOPAT 326.8m / Invested Capital 1.99b)
WACC = 10.43% (E(5.15b)/V(5.35b) * Re(10.79%) + D(209.4m)/V(5.35b) * Rd(2.05%) * (1-Tc(0.25)))
Discount Rate = 10.79% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 55.56 | Cagr: 1.12%
[DCF] Terminal Value 71.55% ; FCFF base≈453.7m ; Y1≈520.1m ; Y5≈765.5m
[DCF] Fair Price = 126.6 (EV 8.42b - Net Debt -135.0m = Equity 8.56b / Shares 67.6m; r=10.43% [WACC]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 99.43 | EPS CAGR: 35.88% | SUE: -0.12 | # QB: 0
Revenue Correlation: 95.99 | Revenue CAGR: 16.99% | SUE: 0.72 | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.86 | Chg30d=-6.08% | Revisions=-29% | Analysts=5
EPS next Quarter (2026-09-30): EPS=1.12 | Chg30d=-2.44% | Revisions=-38% | Analysts=5
EPS current Year (2026-12-31): EPS=4.71 | Chg30d=-0.15% | Revisions=+38% | GrowthEPS=+6.2% | GrowthRev=+10.0%
EPS next Year (2027-12-31): EPS=5.62 | Chg30d=-1.07% | Revisions=+29% | GrowthEPS=+19.3% | GrowthRev=+12.0%
[Analyst] Revisions Ratio: +0% (up=9, down=9)